INDGN - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 3.7
| Stock Code | INDGN | Market Cap | 12,189 Cr. | Current Price | 506 ₹ | High / Low | 633 ₹ |
| Stock P/E | 57.6 | Book Value | 86.4 ₹ | Dividend Yield | 0.39 % | ROCE | 14.3 % |
| ROE | 10.7 % | Face Value | 2.00 ₹ | DMA 50 | 499 ₹ | DMA 200 | 515 ₹ |
| Chg in FII Hold | -1.21 % | Chg in DII Hold | 0.23 % | PAT Qtr | 72.1 Cr. | PAT Prev Qtr | 34.8 Cr. |
| RSI | 50.9 | MACD | 7.24 | Volume | 77,925 | Avg Vol 1Wk | 1,52,110 |
| Low price | 414 ₹ | High price | 633 ₹ | PEG Ratio | 3.26 | Debt to equity | 0.03 |
| 52w Index | 42.0 % | Qtr Profit Var | 33.0 % | EPS | 8.80 ₹ | Industry PE | 40.0 |
📊 Financials: Indegene (INDGN) reports quarterly PAT of ₹72.1 Cr, up from ₹34.8 Cr, showing strong profit growth (+33%). ROE at 10.7% and ROCE at 14.3% are moderate, reflecting decent efficiency. Debt-to-equity ratio of 0.03 highlights a near debt-free balance sheet, ensuring financial stability. EPS of ₹8.80 supports profitability, though margins remain modest relative to valuation.
💹 Valuation: P/E ratio of 57.6 is significantly above industry average (40.0), suggesting premium valuation. Book value of ₹86.4 vs current price ₹506 shows the stock trades at a steep premium. PEG ratio of 3.26 indicates growth is priced in. Dividend yield of 0.39% provides minimal income support. Intrinsic value appears lower than current market price, reflecting overvaluation risk.
🏦 Business Model: Indegene operates in healthcare solutions, digital transformation, and life sciences services. Its competitive advantage lies in specialized expertise, global client base, and technology-driven offerings. Strong demand for healthcare digitalization supports long-term growth, though valuation risks remain.
📈 Entry Zone: Safer entry near ₹440–470, closer to support levels. Current price reflects premium valuation. Long-term holding is viable if earnings growth sustains and efficiency improves, but investors should be cautious of overvaluation.
Positive
- ✅ Strong quarterly PAT growth (+33%).
- ✅ Near debt-free balance sheet (Debt-to-equity 0.03).
- ✅ Expanding healthcare digitalization market supports demand.
Limitation
- ⚠️ High P/E ratio (57.6) vs industry average (40.0).
- ⚠️ PEG ratio of 3.26 indicates growth is fully priced in.
- ⚠️ Dividend yield of 0.39% offers limited income support.
Company Negative News
- 📉 FII holdings decreased (-1.21%), showing reduced foreign investor confidence.
- 📉 Premium valuation raises risk of correction.
Company Positive News
- 📈 DII holdings increased (+0.23%), reflecting domestic institutional support.
- 📈 Strong profit growth boosts investor sentiment.
Industry
- 🏥 Healthcare services sector trades at average P/E of 40.0, lower than Indegene’s valuation.
- 🏥 Rising demand for digital healthcare solutions supports growth.
- 🏥 Sector benefits from global expansion but faces regulatory challenges.
Conclusion
🔎 Indegene is financially stable with strong profit growth and near debt-free status. However, premium valuation and modest efficiency limit upside potential. Entry near ₹440–470 offers better risk-reward balance. Long-term holding is suitable if earnings momentum continues and digital healthcare demand sustains, but caution is warranted due to overvaluation.
For a sharper perspective, we could compare Indegene with Syngene International or Biocon to highlight differences in valuation and profitability across healthcare and life sciences companies.